These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 15623647

  • 21. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
    Gritzapis AD, Mahaira LG, Perez SA, Cacoullos NT, Papamichail M, Baxevanis CN.
    Cancer Res; 2006 May 15; 66(10):5452-60. PubMed ID: 16707474
    [Abstract] [Full Text] [Related]

  • 22. Generation of cytotoxic T-lymphocytes to a self-peptide/class I complex: a model for peptide-mediated tumor rejection.
    Tjoa BA, Kranz DM.
    Cancer Res; 1994 Jan 01; 54(1):204-8. PubMed ID: 7505197
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique.
    Imura K, Ueda Y, Hayashi T, Itoh T, Shimizu K, Tamai H, Yano Y, Naito K, Kohara J, Nakane K, Matsuura Y, Takeda A, Takeda T, Kawai K, Yamagishi H.
    Int J Oncol; 2006 Sep 01; 29(3):531-9. PubMed ID: 16865268
    [Abstract] [Full Text] [Related]

  • 25. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more.
    Kandil DH, Cooper K.
    Adv Anat Pathol; 2009 Mar 01; 16(2):125-9. PubMed ID: 19550373
    [Abstract] [Full Text] [Related]

  • 26. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang RH, Maslak P, Scheinberg DA.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [Abstract] [Full Text] [Related]

  • 27. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary.
    Esheba GE, Pate LL, Longacre TA.
    Am J Surg Pathol; 2008 Apr 01; 32(4):600-7. PubMed ID: 18277882
    [Abstract] [Full Text] [Related]

  • 28. Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice.
    Lozupone F, Rivoltini L, Luciani F, Venditti M, Lugini L, Cova A, Squarcina P, Parmiani G, Belardelli F, Fais S.
    Eur J Immunol; 2003 Feb 01; 33(2):556-66. PubMed ID: 12645955
    [Abstract] [Full Text] [Related]

  • 29. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
    Boukerche H, Baril P, Tabone E, Bérard F, Sanhadji K, Balme B, Wolf F, Perrot H, Thomas L.
    Cancer Res; 2000 Oct 15; 60(20):5848-56. PubMed ID: 11059782
    [Abstract] [Full Text] [Related]

  • 30. Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.
    Xu JJ, Yao K, Yu CJ, Chen X, Lu MP, Sun H, Li BZ, Ding CN, Zhou F.
    Auris Nasus Larynx; 2006 Dec 15; 33(4):441-6. PubMed ID: 16934422
    [Abstract] [Full Text] [Related]

  • 31. Glypican 3: a novel marker in testicular germ cell tumors.
    Zynger DL, Dimov ND, Luan C, Teh BT, Yang XJ.
    Am J Surg Pathol; 2006 Dec 15; 30(12):1570-5. PubMed ID: 17122513
    [Abstract] [Full Text] [Related]

  • 32. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts.
    Nagata Y, Furugen R, Hiasa A, Ikeda H, Ohta N, Furukawa K, Nakamura H, Furukawa K, Kanematsu T, Shiku H.
    J Immunol; 1997 Aug 01; 159(3):1336-43. PubMed ID: 9233630
    [Abstract] [Full Text] [Related]

  • 33. [Effect of tumor antigen specific CTL induced by dendritic cells on a model of human hepatocellular carcinoma in nude mice (LCI-D20)].
    Chen GL, Hu HD, Ma YJ, Li YG, Xue Q, Chen M, Ren H.
    Zhonghua Gan Zang Bing Za Zhi; 2006 Jun 01; 14(6):431-4. PubMed ID: 16792867
    [Abstract] [Full Text] [Related]

  • 34. GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice.
    Li SQ, Lin J, Qi CY, Fu SJ, Xiao WK, Peng BG, Liang LJ.
    Hepatogastroenterology; 2014 Jun 01; 61(130):278-84. PubMed ID: 24901124
    [Abstract] [Full Text] [Related]

  • 35. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
    Yang B, He Y, Sun DL, Zou Y, Qin XH, Huang BH.
    Zhonghua Yi Xue Za Zhi; 2008 Jul 22; 88(28):1956-60. PubMed ID: 19062734
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Cytotoxic T cell immunity against the non-immunogenic, murine, hepatocellular carcinoma Hepa1-6 is directed towards the novel alternative form of macrophage colony stimulating factor.
    Ge L, Zhang JG, Samathanam CA, Delgado C, Tarbiyat-Boldaji M, Dan Q, Hoa N, Nguyen TV, Alipanah R, Pham JT, Sanchez R, Wepsic HT, Morgan TR, Jadus MR.
    Cell Immunol; 2009 Jul 22; 259(2):117-27. PubMed ID: 19615673
    [Abstract] [Full Text] [Related]

  • 38. [The cancer specific antigen, glypican-3 (GPC3)-targeted immunotherapy].
    Sawada Y, Nakatsura T.
    Nihon Rinsho; 2012 Dec 22; 70(12):2136-41. PubMed ID: 23259386
    [Abstract] [Full Text] [Related]

  • 39. Generation of chimeric HBc proteins with epitopes in E.coli: formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo.
    Zhang Y, Song S, Liu C, Wang Y, Xian X, He Y, Wang J, Liu F, Sun S.
    Cell Immunol; 2007 May 22; 247(1):18-27. PubMed ID: 17707782
    [Abstract] [Full Text] [Related]

  • 40. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors.
    Nagaraj S, Pisarev V, Kinarsky L, Sherman S, Muro-Cacho C, Altieri DC, Gabrilovich DI.
    J Immunother; 2007 May 22; 30(2):169-79. PubMed ID: 17471164
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.